CALL FOR PAPERS

CERTIFICATE

IMPACT FACTOR 2018

Subject Area

  • Life Sciences / Biology
  • Architecture / Building Management
  • Asian Studies
  • Business & Management
  • Chemistry
  • Computer Science
  • Economics & Finance
  • Engineering / Acoustics
  • Environmental Science
  • Agricultural Sciences
  • Pharmaceutical Sciences
  • General Sciences
  • Materials Science
  • Mathematics
  • Medicine
  • Nanotechnology & Nanoscience
  • Nonlinear Science
  • Chaos & Dynamical Systems
  • Physics
  • Social Sciences & Humanities

Why Us? >>

  • Open Access
  • Peer Reviewed
  • Rapid Publication
  • Life time hosting
  • Free promotion service
  • Free indexing service
  • More citations
  • Search engine friendly

Plagiarism Detection

IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.

Cellular immunity of Ashwagandha against doxorubicin toxicity

Author: 
Mohammad Ali, Tarique Faizi Rizvi, Md. Razauddin, Talat Jahan, Zeba Naz, Md. Seemab Akhter, Ranjit Kumar, Prabhat Shankar and Arun Kumar
Subject Area: 
Life Sciences
Abstract: 

Doxorubicin is one of the important antitumor agents having a variety of therapeutic potency against variety of human tumors including soft tissue sarcoma, breast cancer, small cell carcinoma of the lung and acute leukemias. Similarly it has toxic effect on various parts of the body especially on immune system and heart. Whenever this drug is used on cancer patients, its toxicity acts on immune system of the patients by depressing the bone marrow. It has been suggested that Ashwagandha plays an important role in immune system regulation, but its impact on toxicity produced by cancer chemotherapy is still obscure. In present investigation to evaluate the efficacy of Ashwagandha against Doxorubicin (anti cancer drug) toxicity lymphocyte subpopulations activity was examined in Rats. After administration of Doxorubicin @ 5 mg/kg b.w. Intraperitoneal (I.P.) to rats marked reduction in the number of CD8+ cells and in the proportion of CD4+ cells were observed on day 21st. When Ashwagandha (300mg/kg b.w.) administered five days prior to Doxorubicin administration and continued for 21 days ((21 days was counted from the first exposure of Doxorubicin)) then significant increase in the number of CD8+ cells and in the proportion of CD4+ cells were observed. Thus findings of present investigation showed that Ashwagandha acts as an immunomodulator for cellular immunity and ameliorate the toxicity produced during cancer chemotherapy by mitigating the bone marrow depression.

PDF file: 

IJMCE RECOMMENDATION

ONLINE PAYPAL PAYMENT

CURRENT ISSUE

NEWS

CHIEF EDITOR
Rosane Cavalcante Fragoso, Brasil
ASSOCIATE CHIEF EDITOR

   

Jean-Marc SABATIER
Chief Scientific Officer and Head of a Research Group
France

Advantages of IJCR

  • Rapid Publishing
  • Professional publishing practices
  • Indexing in leading database
  • High level of citation
  • High Qualitiy reader base
  • High level author suport

EDITORIAL BOARD

Luai Farhan Zghair
Iraq
Hasan Ali Abed Al-Zu’bi
Jordanian
Fredrick OJIJA
Tanzanian
Firuza M. Tursunkhodjaeva
Uzbekistan
Faraz Ahmed Farooqi
Saudi Arabia
Eric Randy Reyes Politud
Philippines
Elsadig Gasoom FadelAlla Elbashir
Sudan
Eapen, Asha Sarah
United State
Dr.Arun Kumar A
India
Dr. Zafar Iqbal
Pakistan
Dr. SHAHERA S.PATEL
India
Dr. Ruchika Khanna
India
Dr. Recep TAS
Turkey
Dr. Rasha Ali Eldeeb
Egypt
Dr. Pralhad Kanhaiyalal Rahangdale
India
DR. PATRICK D. CERNA
Philippines
Dr. Nicolas Padilla- Raygoza
Mexico
Dr. Mustafa Y. G. Younis
Libiya
Dr. Muhammad shoaib Ahmedani
Saudi Arabia
DR. MUHAMMAD ISMAIL MOHMAND
United State
DR. MAHESH SHIVAJI CHAVAN
India
DR. M. ARUNA
India
Dr. Lim Gee Nee
Malaysia
Dr. Jatinder Pal Singh Chawla
India
DR. IRAM BOKHARI
Pakistan
Dr. FARHAT NAZ RAHMAN
Pakistan
Dr. Devendra kumar Gupta
India
Dr. ASHWANI KUMAR DUBEY
India
Dr. Ali Seidi
Iran
Dr. Achmad Choerudin
Indonesia
Dr Ashok Kumar Verma
India
Thi Mong Diep NGUYEN
France
Dr. Muhammad Akram
Pakistan
Dr. Imran Azad
Oman
Dr. Meenakshi Malik
India
Aseel Hadi Hamzah
Iraq
Anam Bhatti
Malaysia
Md. Amir Hossain
Bangladesh
Ahmet İPEKÇİ
Turkey
Mirzadi Gohari
Iran